For 2025, Edwards Lifesciences (NYSE:EW) projects constant currency sales growth of 8% to 10%, with adjusted EPS between $2.40 and $2.50. Transcatheter Aortic Valve Replacement sales are expected ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Edwards Lifesciences Corporation (NYSE ... As we noted earlier this year, the Company's flagship transcatheter aortic valve replacement (TAVR) franchise slowed as compared to the Company's recent ...

These techniques include coronary sinus annuloplasty, direct annuloplasty, leaflet repair ... (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional ...

He has also acted as a Consultant for Sorin and received research support from Edwards Lifesciences. Jean G. Dumesnil received Speakers' Bureau honoraria from Medtronic and St Jude Medical.

Annual Meeting reveals that mechanical aortic valve replacements (AVRs) provide significant long-term survival benefits for ...

SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...